Vault-13

Sands Capital Alternatives, LLC

ARLINGTON, VA · CIK 1846444 · 13F filing filed 2022-08-12

SEC-registered investment adviser since 2011 · limited liability company

As an employer

Where they work

people there (dot area)number not reportedmain officeHover or tap a dot. Australian and UK companies are placed at their business or registered address, with their staff across the whole country.

Offices

From Form ADV: the main office and the other offices where it does advisory work (at most the 25 largest), with the people doing investment work at each. “About” is worked out: the firm's investment staff less its other offices. Each city links to the other managers there.

CityCountryPeople
Arlington, VA (main office)United States United Statesabout 60
Fitzrovia LondonUnited Kingdom United Kingdom2
San Francisco, CAUnited States United States2
New York City, NYUnited States United States1
San Juan, PRUnited States United States1
SingaporeSingapore Singapore

Map: places from GeoNames (CC BY 4.0), outlines from Natural Earth.

$364.2m reported value -23.9% vs Q1 2022
19positions
90.3%in top 10
1 new 1 added 1 reduced 0 sold out vs Q1 2022

Holdings, Q2 2022

The small lines show how much was held over the last 4 quarters (adjusted for stock splits).

#SecurityTickerShares Value% of portfolioChangeShares change
1 UIPATH INC CL A PATH PATH 3,811,779 $69.3m19.04% 19.04% UnchangedShares held: Q3 2021 3.8m, Q4 2021 3.8m, Q1 2022 3.8m, Q2 2022 3.8m
2 DICE THERAPEUTICS INC COM COM 3,148,970 $48.9m13.42% 13.42% UnchangedShares held: Q3 2021 3.1m, Q4 2021 3.1m, Q1 2022 3.1m, Q2 2022 3.1m
3 DOORDASH INC CL A DASH DASH 601,454 $38.6m10.60% 10.60% UnchangedShares held: Q3 2021 630.2k, Q4 2021 601.5k, Q1 2022 601.5k, Q2 2022 601.5k
4 NU HLDGS LTD ORD SHS CL A NU NU 9,136,835 $34.2m9.38% 9.38% UnchangedShares held: Q3 2021 0, Q4 2021 9.1m, Q1 2022 9.1m, Q2 2022 9.1m
5 SAMSARA, INC. COM CL B COM CL B 2,712,256 $30.3m8.32% 8.32% UnchangedShares held: Q3 2021 0, Q4 2021 2.7m, Q1 2022 2.7m, Q2 2022 2.7m
6 SNOWFLAKE INC CL A SNOW SNOW 214,621 $29.8m8.20% 8.20% UnchangedShares held: Q3 2021 316.6k, Q4 2021 214.6k, Q1 2022 214.6k, Q2 2022 214.6k
7 KARUNA THERAPEUTICS INC COM COM 172,895 $21.9m6.01% 6.01% ReducedShares held: Q3 2021 267.9k, Q4 2021 267.9k, Q1 2022 267.9k, Q2 2022 172.9k -95.0k -95,000 -35.5%
8 10X GENOMICS INC CL A COM TXG TXG 481,770 $21.8m5.99% 5.99% NewShares held: Q3 2021 0, Q4 2021 0, Q1 2022 0, Q2 2022 481.8k
9 CINCOR PHARMA INC COM COM 950,000 $17.9m4.91% 4.91% UnchangedShares held: Q3 2021 0, Q4 2021 0, Q1 2022 950.0k, Q2 2022 950.0k
10 ACUMEN PHARMACEUTICALS INC COM ABOS ABOS 3,417,075 $16.1m4.41% 4.41% UnchangedShares held: Q3 2021 3.4m, Q4 2021 3.4m, Q1 2022 3.4m, Q2 2022 3.4m
11 OLINK HLDG AB SPONSORED ADS SPONSORED ADS 705,514 $10.7m2.94% 2.94% AddedShares held: Q3 2021 0, Q4 2021 0, Q1 2022 425.5k, Q2 2022 705.5k +280.0k +280,000 65.8%
12 908 DEVICES INC COM MASS MASS 326,427 $6.7m1.85% 1.85% UnchangedShares held: Q3 2021 326.4k, Q4 2021 326.4k, Q1 2022 326.4k, Q2 2022 326.4k
13 TARSUS PHARMACEUTICALS INC COM TARS TARS 260,000 $3.8m1.04% 1.04% UnchangedShares held: Q3 2021 260.0k, Q4 2021 260.0k, Q1 2022 260.0k, Q2 2022 260.0k
14 REPLIGEN CORP COM RGEN RGEN 22,544 $3.7m1.01% 1.01% UnchangedShares held: Q3 2021 22.5k, Q4 2021 22.5k, Q1 2022 22.5k, Q2 2022 22.5k
15 SAMSARA INC COM CL A IOT IOT 326,000 $3.6m1.00% 1.00% UnchangedShares held: Q3 2021 0, Q4 2021 326.0k, Q1 2022 326.0k, Q2 2022 326.0k
16 TAYSHA GENE THERAPIES INC COM SHS TSHA TSHA 724,873 $2.7m0.74% 0.74% UnchangedShares held: Q3 2021 724.9k, Q4 2021 724.9k, Q1 2022 724.9k, Q2 2022 724.9k
17 CANDEL THERAPEUTICS INC COM CADL CADL 811,737 $2.6m0.72% 0.72% UnchangedShares held: Q3 2021 811.7k, Q4 2021 811.7k, Q1 2022 811.7k, Q2 2022 811.7k
18 SPRUCE BIOSCIENCES INC COM COM 787,007 $1.4m0.38% 0.38% UnchangedShares held: Q3 2021 787.0k, Q4 2021 787.0k, Q1 2022 787.0k, Q2 2022 787.0k
19 ABSCI CORPORATION COM ABSI ABSI 57,804 $192.0k0.05% 0.05% UnchangedShares held: Q3 2021 57.8k, Q4 2021 57.8k, Q1 2022 57.8k, Q2 2022 57.8k

Stakes above 5%

Companies where this manager has reported owning more than 5% of a class of shares, on Schedule 13D (may seek influence) or 13G (passive): its latest filing for each, from 19 Dec 2024 on.

CompanyTickerStakeChange ScheduleLast filed
ACUMEN PHARMACEUTICALS INC ABOS · 13G · filed 2025-08-13 ABOS 5.6%≈ $9.1m 13G 2025-08-13